– CANADA, Calgary – Medicenna Therapeutics Corp. (TSX: MDNA), a clinical stage immuno-oncology company, today announced that it has appointed Dr. William Li to its Board of Directors.

“We are delighted to appoint such an outstanding and experienced oncology drug development expert to our Board of Directors” said Dr. Fahar Merchant, Chairman, President and CEO, “Dr. W. Li adds depth to our existing Board as we position ourselves for clinical success in 2018.”

Dr. William Li is a seasoned executive, leading innovation in cancer therapeutics, diagnostics, and imaging for over two decades. He is CEO, President and Co-Founder of the Angiogenesis Foundation and has served as executive strategic consultant in oncology drug development for Bayer, Genentech, Sanofi-Aventis, Novartis, Pfizer, among others, and advised leaders at major investment banks. As an eminent oncology innovator, Dr. Li has collaborated with major medical academic centers, biopharmaceutical companies and government agencies, including the NIH, NCI and the FDA. Dr. Li has extensive expertise in tumor angiogenesis, in vivo angiogenesis models, angiogenesis therapeutic development and clinical trials. He is a published author in leading research journals, peer reviewed publications and has been a speaker at TED. A graduate of Harvard College and the University of Pittsburgh School of Medicine, Dr. Li completed his residency training at the Massachusetts General Hospital. Dr. Li has held appointments on the clinical faculties of Harvard Medical School, Tufts University, and at Dartmouth Medical School. He is currently a member of the board of directors of another immuno-oncology company, Leap Therapeutics, Inc (LPTX, Nasdaq).

About Medicenna Therapeutics Corp.

Medicenna is a clinical stage immuno-oncology company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines™ and first in class Empowered Cytokines™ (ECs). Its wholly owned subsidiary, Houston-based Medicenna BioPharma, is specifically targeting the Interleukin-4 Receptor (IL4R), which is over-expressed by at least 20 different types of cancer affecting more than one million new cancer patients every year. Medicenna’s lead IL4-EC, MDNA55 is enrolling patients in a Phase 2b clinical trial for rGBM at leading brain cancer centres in the US. MDNA55 has completed 3 clinical trials in 72 patients, including 66 adults with rGBM, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from USFDA. Unlike most other cancer therapies, Medicenna’s IL4-ECs have the potential to purge both the tumor and the immunosuppressive tumor microenvironment, offering a unique treatment paradigm for a large majority of cancer patients.

For more information : http://www.medicenna.com

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

here the original post =>

Comments are closed.